PRE-APPROVAL INSPECTION ISSUES DELAY BIMEKIZUMAB APPROVAL FOR SEVERE PLAQUE PSORIASIS – May 13, 2022.
 
Human Ventricular Progenitor Cells Promote the Formation of New Heart Tissue After MI – May 13, 2022

 

GUT MICROBIOME COMPOSITION PREDICTIVE OF PATIENT RESPONSE TO STATINS – May 12, 2022

 

National Lockdown in North Korea as ‘First’ Covid Case Reported – May 12, 2022

 

tiragolumab + Tecentriq Fails to meet Endpoints in Phase II trial  of NSCLC – May 11, 2022

 

PFIZER TO ACQUIRE BIOHAVEN PHARMACEUTICALS FOR $11.6 BLN – MAY 10, 2022
 
YOUNGER CANCER PATIENTS ARE A HIGH-RISK FOR POOR OUTCOMES FROM COVID-19 INFECTION – MAY 9, 2022
 
HYPERTENSIVE DISORDERS DURING PREGNANCY LINKED TO INCREASED CVD RISK – MAY 9, 2022

 

GENDER SPECIFIC RISK FACTORS MAY PREDICT HEART ATTACKS IN YOUNG ADULTS – May 6, 2022
 
Omicron risks of hospitalization and mortality almost identical to other Variants – May 5, 2022
 
FDA Grants Imfinzi plus chemotherapy Priority Review for locally advanced or metastatic biliary tract cancer – May 4, 2022
 
PROCURE Study: The Importance of gene expression profile testing in guiding treatment decisions for early-stage breast cancer – May 4, 2022
 
FDA APPROVES CUVRIOR™ FOR PATIENTS WITH STABLE WILSON’S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE– MAY 3, 2022

 

INSULIN NASAL SPRAY MAY IMPROVE BRAIN HEALTH, & PREVENT ALZHEIMER’S IN NON-DIABETICS – MAY 3, 2022
 
FDA DECLINES APPROVAL OF 2 CANCER MEDS TESTED IN CHINA – MAY 2, 2022
 
AMERICAN ACADEMY OF PEDIATRICS CALLS FOR ELIMINATION OF RACE-BASED MEDICINE – MAY 2, 2022
 
cdc rEPORTS: fIRST us Case of Human Avian Influenza A(H5) – aPRIL 29, 2022
 
CAMZYOS™ (MAVACAMTEN) APPROVED FOR SYMPTOMATIC CLASS  II – III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY – April 29, 2022
 
PFIZER RESTARTS PHASE 3 CIFFREO GENE THERAPY TRIAL – April 28, 2022
 
NEW MODEL PREDICTS PATIENTS WITH POOR LUNG CANCER OUTCOMES – APRIL 27, 2022
HUMAN CASE OF H3N8 BIRD FLU REPORTED IN HENAN CHINA – APRIL 27, 2022
POSITIVE PHASE 2 PEDIATRIC DATA FOR LYME DISEASE VACCINE CANDIDATE – APRIL, 26, 2022
 
NEKTAR CUTS 70% OF WORKFORCE – APRIL 26, 2022
 
Drug-resistant form of Aspergillus fumigatus (environmental mold) capable of infecting people – April 25, 2022

 

War in Ukraine Disrupts multiple sclerosis drug development – April 25, 2022
 
WHO: 1 Death and 169 Cases of Pediatric Hepatitis Reported in 12 Countries – April 24, 2022

 

THE DIFFERENCE BETWEEN LONG COVID AND PERSISTENT COVID – APRIL 22, 2022
 
CDC UPDATE ON PEDIATRIC HEPATITIS CASES OF UNKNOWN ORIGIN – APRIL 22, 2022
 
AMERICAN LUNG ASSOCIATION:137 MILLION AMERICANS LIVE WITH UNHEALTHY AIR POLLUTION – APRIL 21, 2022
 
WHITE HOUSE SENDING NATIONAL DRUG CONTROL STRATEGY TO CONGRESS – APRIL 21, 2022
 
BOEHRINGER INGELHEIM AND LILLY LAUNCH HEAR YOUR HEART™ TO EMPOWER WOMEN WITH HEART FAILURE – APRIL 20, 2022
 
FDA CITES CONCERNS OVER TEVA AND MEDINCELL’ S EXTENDED-RELEASE RISPERIDONE FOR SCHIZOPHRENIA  – April 20, 2022
 
AbbVie ends collaboration agreement with BioArctic  – April 20, 2022
 
FDA DRAFT GUIDANCE ON FOOD ALLERGENS AVAILABLE FOR COMMENT – APRIL 19, 2022
 
Achieving Treatment Goals Likely Extends in Life Expectancy in Type 2 Diabetes – April 18, 2022
 
WHO AND CDC LOOKING INTO RARE PEDIATRIC HEPATITIS – April 17, 2022
 
Nektar and BMS Halt Studies of Bempegaldesleukin + Nivolumab in Cancer – April 15, 2022
 
Top Pharma Companies by Revenue in 2021 – April 15, 2022
 
Study Identifies Difference Between Pfizer and Moderna COVID Vaccine antibodies – April 15, 2022
 
Combination therapies show better outcomes for HR-positive, ERBB2-negative MB – April 14, 2022
 
2021 was the deadliest year in U.S. history – April 13, 2022
 
FDA and DEA Warning: Online Pharmacies Illegally Selling Adderall – April 13, 2022
 
CHILDREN WITH BIRTH DEFECTS HAVE A HIGH RISK OF POST NEONATAL MORTALITY– APRIL 12, 2022
 
FDA LIFTS PARTIAL CLINICAL HOLD ON MDS AND AML MAGROLIMAB STUDIES – APRIL 12, 2022
 
LEBRIKIZUMAB + TOPICAL CORTICOSTEROIDS SHOWS SIGNIFICANT IMPROVEMENTS IN ATOPIC DERMATITIS – APRIL 11, 2022
 
CAR T-CELL THERAPY FOR SOLID TUMORS SHOWS EARLY EFFICACY – APRIL 11, 2022
 
FDA PARTIAL CLINICAL HOLD FOR TAKEAIM LYMPHOMA STUDY OF EMAVUSERTIB – APRIL 11, 2022
 
CMS LIMITS COVERAGE FOR BIOGEN’S ADUHELM TO CLINICAL TRIALS – APRIL 8, 2022
 
ANTI-PD-1 TISLELIZUMAB ACCEPTED BY EMA FOR REGULATORY REVIEW IN ESOPHAGEAL AND LUNG CANCERS
 – APRIL 8, 2022
 
COVID CASES RISING AGAIN IN THE US – INTERACTIVE STATE MAP – APRIL 7, 2022
 
ACADIA PHARMACEUTICALS TO SUBMIT TROFINETIDE FOR RETT SYNDROME TO FDA – APRIL 7, 2022
 
PERSONALITY TRAITS OF SELF-MADE AND INHERITED MILLIONAIRES – APRIL 6, 2022
 
MEDICARE COVERS 8 OVER-THE-COUNTER COVID-19 TESTS PER MONTH – APRIL 5, 2022
 
PEOPLE WITH A STRONGER BELIEF IN EVOLUTION MORE LIKELY SUPPORTIVE OF SOCIAL AND RACIAL DIFFERENCES – APRIL 5, 2022
 
CDC HIRES OUTSIDE OFFICIAL FOR REVIEW – PLANS RESTRUCTURE – APRIL 5, 2022
 
NORMAN SHARPLESS STEPS DOWN AS DIRECTOR OF THE NATIONAL CANCER INSTITUTE– APRIL 4, 202